NCT01650779View on ClinicalTrials.gov

A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta

PHASE4CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Fabry Disease
Interventions
BIOLOGICAL

Agalsidase beta

Commercially available agalsidase beta 1.0 mg/kg administered as an intravenous infusion q2w up to Month 6.

Trial Locations (6)

Unknown

Coral Springs

Decatur

Baltimore

Grand Rapids

Hellertown

Fairfax

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT01650779 - A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta | Biotech Hunter | Biotech Hunter